Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 4/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26553563 | 0.92 | CTSD (0.38) | CTSDCTSLCTSBCTSSSIGMAR1 | |
| SCHEMBL24029912 | 0.88 | SIGMAR1 (0.44) | CTSDCTSLCTSBCTSSSIGMAR1 | |
| SCHEMBL26551028 | 0.81 | KDM4E (0.35) | TSHRGAAALOX15ALDH1A1TDP1 | |
| SCHEMBL26553584 | 0.79 | TDP1 (0.37) | GAAMEN1KMT2ATDP1CNR1 | |
| SCHEMBL24029970 | 0.79 | CTSD (0.43) | CTSDCTSLCTSBCTSSSIGMAR1 | |
| SCHEMBL24029914 | 0.79 | KDM4E (0.34) | TSHRGAAALOX15ALDH1A1MEN1 | |
| SCHEMBL24029964 | 0.78 | DRD2 (0.49) | SIGMAR1TSHRTDP1DRD2CNR1 | |
| SCHEMBL26553378 | 0.76 | TDP1 (0.42) | GAAALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL24030147 | 0.75 | CTSD (0.37) | CTSDCTSLCTSBCTSSTSHR | |
| SCHEMBL26570547 | 0.73 | TDP1 (0.36) | GAAMEN1KMT2ATDP1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331761-A1 | Aryl Glucoside Derivative, Preparation Method Therefor And Application Thereof | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| WO-2021227440-A1 | A CLASS OF ARYL GLUCOSIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海喆邺生物科技有限公司 | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331761-A1 | Aryl Glucoside Derivative, Preparation Method Therefor And Application Thereof | SLC5A1, SLC5A2, SLC10A1 | CTSD 3612/4885CTSL 2660/4885CTSB 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.